Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• Schizophrenia is a polygenic disorder linked to altered synaptic homeostasis.
• Complement component 4 (C4) gene variants strongly associate with schizophrenia, impacting synaptic pruning via microglia.
• Overactive microglia and reduced synaptic density in the prefrontal cortex (PFC) are hallmarks of schizophrenia.

Purpose of the Study:

• To explore the potential of psychedelics in treating schizophrenia.
• To investigate if psychedelics can counteract synaptic loss and promote neuroplasticity in schizophrenia.

Main Methods:

• Review of preclinical evidence (in vitro and animal models) on psychedelic effects on neuroplasticity.
• Consideration of in vivo studies using SV2A radioligands to assess synaptic density in schizophrenia patients.

Main Results:

• Preclinical studies show psychedelics promote neuroplasticity and synaptogenesis.
• Lower synaptic density in the PFC of schizophrenia patients confirmed by SV2A imaging.
• Potential for psychedelics to restore volume loss and improve negative/cognitive symptoms.

Conclusions:

• Psychedelics show promise for schizophrenia treatment by enhancing synaptic connections.
• Microdosing psychedelics should be explored first in deficit schizophrenia patients.
• Further research with varying doses may reveal broader therapeutic applications.